99075-25-9

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 2-(4-(AMINOMETHYL)PHENYL)ACETATE HYDROCHLORIDE is used as a synthetic intermediate for the production of various pharmaceuticals. Its role in drug synthesis is crucial due to its ability to contribute to the development of new medications with potential therapeutic effects for treating certain medical conditions.
Used in Drug Synthesis:
METHYL 2-(4-(AMINOMETHYL)PHENYL)ACETATE HYDROCHLORIDE is used as a building block in the preparation of pharmaceutical ingredients. Its chemical structure allows it to be a key component in the creation of diverse drug molecules, enhancing the range of treatments available for various health issues.
Used in Research and Development:
In the field of pharmaceutical research and development, METHYL 2-(4-(AMINOMETHYL)PHENYL)ACETATE HYDROCHLORIDE is utilized for exploring its potential therapeutic effects and understanding its interactions within biological systems. This helps in advancing the knowledge of drug mechanisms and contributes to the innovation of new therapeutic agents.

Upstream product

• 7647-01-0 hydrogenchloride 
• 191871-32-6 [4-(tert-butoxycarbonylamino-methyl)-phenyl]-acetic acid methyl ester 
• 383653-04-1 (3R,5S)-N-propanesulfonyl-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide 

Downstream Products

• 1005513-88-1 Methyl {4-[({[1-(3-{[tert-butyl(dimethyl)silyl]oxy}propyl)-1H-imidazol-2-yl]methyl}amino)methyl]phenyl}acetate 
• 1349698-70-9 (4-{[(5-bromo-1-methyl-1H-pyrazole-3-carbonyl)amino]methyl}phenyl)acetic acid methyl ester 
• 808753-29-9 methyl 2-(4-(phenylsulfonamidomethyl)phenyl)acetate 
• 1352732-15-0 2-(4-(benzamidomethyl)phenyl)acetic acid 
• 191869-84-8 (R)-N₅-[Amino(nitroimino)methyl]-N-[[4-(carboxymethyl)-phenyl]methyl]-N₂-(diphenylacetyl)-ornithinamide 
• 1428732-00-6 methyl 2-(4-(benzamidomethyl)phenyl)acetate 

Relevant academic research and scientific papers

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES AS GLUTAMINASE INHIBITORS FOR TREATING CANCERS THEREOF

Provided are compounds of formula (I), wherein X, Y, Z, W, m, n, o, p, R1, R2 and R6 are defined as in the description. Pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof are also provided.

Sulfonylamino phenylacetamide derivatives and methods of their use

Sulfonylamino phenylacetamide derivatives of the general formula are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed. In certain embodiments, the compounds of the invention that, preferably: (1) bind with high affinity to κ opioid receptors; (2) display good opioid receptor selectivity of κ versus μ and κ versus δ; and (3) do not substantially inhibit cytochrome P450 enzymatic activity, in particular CYP2D6, CYP2C9 and CYP3A4.

Benzoxazepinones and their use as squalene synthase inhibitors

There is disclosed a compound represented by the formula [I]: wherein R1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, -X1-X2-Ar-X3-X4-COOH (wherein X1 and X4 are a bond or alkylene group, X2 and X3 are a bond, -O-, -S-, Ar is divalent aromatic group etc.), R2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.

AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM

The invention relates to new amino acid derivatives of general formula (I), wherein B, T, Z, Y, V and n are defined as in claim 1, the tautomers, diastereomers and enantiomers thereof, the mixtures thereof and the salts thereof, particularly their physiologically acceptable salts with inorganic or organic acids or bases which have valuable pharmacological properties, particularly selective NPY-antagonist properties, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them.

Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them

NPY-antagonistic compounds of the formula STR1 Exemplary are: (A) (R)-N-[[4-(Aminocarbonylaminomethyl)phenyl]methyl]-N 2-bis(4-hydroxyphenyl)acetyl]-argininamide-trifluoracetate;(B) (R)-N-[[4-(Aminocarbonylaminomethyl)phenyl]methyl]-N 2-[bis(4-chlorphenyl)acetyl]-argininamide-trifluoracetate;(C) (R)-N-[[4-Aminocarbonylaminomethyl)phenyl]methyl]-N 2-(diphenylacetyl)-argininamide-trifluoracetate;(D) (R)-N 2-(Diphenylacetyl)-N-[[4-(ethoxycarbonylmethylamino-carbonylaminomethyl) phenyl]methyl]-argininamide-trifluoroacetate;(E) (R,S)-N 5-(Aminoiminomethyl)-N 2-(diphenylacetyl)-N-[(4-hy-droxyphenyl)methyl]-N 5-methyl-ornithinamide-hydrochloride; (F) (R)-N-[[4-(Aminocarbonylmethyl)phenyl]methyl]-N 2-(diphenyl-acetyl)-argininamide-diacetate;(G) (R)-N. sup. 2-(Diphenylacetyl)-N-[[4-(ethylaminocarbonylamino-methyl)-phenyl]methyl]-argininamide-bis-(trifluoroacetate); and,(H) (R)-N. sup.2-(Diphenylacetyl)-N-[[4-(ethoxycarbonylamino-carbonylaminomethyl) phenyl]methyl]-argininamide-trifluoroacetate.